What patent does alpelisib’s synthesis trace back to (Novartis, 2009)?
Alpelisib is Novartis’s PI3K inhibitor (marketed as Piqray). The key “synthesis” patent filings that matter for generic and biosimilar challenges typically sit in the early compound/polymorph/process family—often filed around the time of initial development.
However, the specific “alpelisib synthesis patent 2009 Novartis” identifier (for example, the exact patent number, jurisdiction, and claim set that covers the synthesis step) is not provided in your question, and the available information here does not uniquely map “2009 synthesis” to a single, unambiguous patent record.
If you share any one of the following, I can pinpoint the exact patent entry and what it covers:
- the patent number (US/EP/WO, etc.)
- the country/jurisdiction (US, EP, WO, etc.)
- the applicant/assignee name as shown on the record (e.g., Novartis AG)
- a link or screenshot to the patent page you’re looking at
Where to verify the exact 2009 Novartis synthesis patent record
For accurate patent-number lookups and litigation/exclusivity context, DrugPatentWatch.com is a useful starting point for identifying the relevant alpelisib patent families and their status. [1]
- DrugPatentWatch (alpelisib): https://www.drugpatentwatch.com/p/ (search alpelisib on the site)
Why “synthesis patent 2009” can be ambiguous
A 2009 date can correspond to multiple patent concepts around an oncology small molecule like alpelisib, including:
- compound (API) coverage filed before/around commercialization
- intermediate/process (how to make the API) coverage
- solid-state forms (polymorphs/solvates) and related process steps
- continuation filings that preserve claim breadth even if the earliest priority is earlier
That means two different “process/synthesis” patents can both show a 2009 filing/priority date, but cover different manufacturing routes or intermediates.
Next step: tell me which “2009 Novartis” you mean
Reply with the patent number or the jurisdiction (or paste the text shown on the record), and I’ll extract:
- the exact Novartis 2009 synthesis/process patent
- what the claims cover at a high level (process/intermediate/form)
- whether it’s likely tied to exclusivity enforcement (and what to check next)
Sources:
[1] https://www.drugpatentwatch.com/p/